MEDNAX (MD) Tops Q3 EPS by 7c, Beats on Revenue; Reaffirms EBITDA Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts MD Hot Sheet
Join SI Premium – FREE
MEDNAX (NYSE: MD) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $501 million versus the consensus estimate of $498.19 million.
Pediatrix anticipates that its full year 2026 outlook for Adjusted EBITDA, as defined above, will be in a range of $290 million to $300 million.
For earnings history and earnings-related data on MEDNAX (MD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Cricut Inc. (CRCT) Tops Q3 EPS by 8c
- Claros Mortgage Trust, Inc. (CMTG) Tops Q3 EPS by 31c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
